The evolving role of information technology in the drug discovery process.

Information technologies for chemical structure prediction, heterogeneous database access, pattern discovery, and systems and molecular modeling have evolved to become core components of the modern drug discovery process. As this evolution continues, the balance between in silico modeling and 'wet' chemistry will continue to shift and it might eventually be possible to step through the discovery pipeline without the aid of traditional laboratory techniques. Rapid advances in the industrialization of gene sequencing combined with databases of protein sequence and structure have created a target-rich but lead-poor environment. During the next decade, newer information technologies that facilitate the molecular modeling of drug-target interactions are likely to shift this balance towards molecular-based personalized medicine -- the ultimate goal of the drug discovery process.

[1]  Paul W. H. I. Parren,et al.  Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41 , 2001, Journal of Virology.

[2]  Ajay K. Royyuru,et al.  Blue Gene: A vision for protein science using a petaflop supercomputer , 2001, IBM Syst. J..

[3]  A. Sali,et al.  Protein Structure Prediction and Structural Genomics , 2001, Science.

[4]  J. V. Moran,et al.  Initial sequencing and analysis of the human genome. , 2001, Nature.

[5]  Benjamin J. Blencowe,et al.  Distinct Factor Requirements for Exonic Splicing Enhancer Function and Binding of U2AF to the Polypyrimidine Tract* , 1999, The Journal of Biological Chemistry.

[6]  Yuhong Wang,et al.  Storing biological sequence databases in relational form , 2000, Bioinform..

[7]  J. Johnson,et al.  Pharmacogenomics: the inherited basis for interindividual differences in drug response. , 2001, Annual review of genomics and human genetics.

[8]  J. Avise,et al.  Evolving genomic metaphors: a new look at the language of DNA. , 2001, Science.

[9]  S. Aparicio,et al.  How to count…human genes , 2000, Nature Genetics.

[10]  D. Mccormick Sequence the Human Genome , 1986, Bio/Technology.

[11]  F. Bernini,et al.  New insights into the pharmacodynamic and pharmacokinetic properties of statins. , 1999, Pharmacology & therapeutics.

[12]  D R Burton,et al.  gp120: Biologic aspects of structural features. , 2001, Annual review of immunology.

[13]  R Gilmour,et al.  Taxonomic markup language: applying XML to systematic data , 2000, Bioinform..

[14]  Joseph Sodroski,et al.  Association of Structural Changes in the V2 and V3 Loops of the gp120 Envelope Glycoprotein with Acquisition of Neutralization Resistance in a Simian-Human Immunodeficiency Virus Passaged In Vivo , 2000, Journal of Virology.

[15]  Roger E Bumgarner,et al.  Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. , 2001, Science.

[16]  Andrzej Galat,et al.  Analysis of dynamics trajectories of DNA and DNA-drug complexes , 1989, Comput. Appl. Biosci..

[17]  Teresa Head-Gordon,et al.  Computational challenges in structural and functional genomics , 2001, IBM Syst. J..

[18]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[19]  W Miller,et al.  Comparison of the Escherichia coli K-12 genome with sampled genomes of a Klebsiella pneumoniae and three salmonella enterica serovars, Typhimurium, Typhi and Paratyphi. , 2000, Nucleic acids research.

[20]  David Yang,et al.  The N-Terminal V3 Loop Glycan Modulates the Interaction of Clade A and B Human Immunodeficiency Virus Type 1 Envelopes with CD4 and Chemokine Receptors , 2000, Journal of Virology.

[21]  Stu Borman PROTEOMICS: Taking Over Where Genomics Leaves Off: Researchers use a variety of tools to prove protein function and interactions, with drug discovery the major goal , 2000 .

[22]  B Nordén,et al.  A simple model for gene targeting. , 2001, Biophysical journal.

[23]  G.E. Moore,et al.  Cramming More Components Onto Integrated Circuits , 1998, Proceedings of the IEEE.

[24]  Celia M. Henry STRUCTURE-BASED DRUG DESIGN , 2001 .

[25]  A. Catapano,et al.  Pharmacology of competitive inhibitors of HMG-CoA reductase. , 1995, Pharmacological research.

[26]  J. Gern The Sequence of the Human Genome , 2001, Science.

[27]  J. Sudbø,et al.  Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.

[28]  R. Stevens,et al.  Global Efforts in Structural Genomics , 2001, Science.

[29]  L. Chasin,et al.  Multiple Splicing Defects in an Intronic False Exon , 2000, Molecular and Cellular Biology.

[30]  Mikhail S. Gelfand,et al.  Algorithms and software for support of gene identification experiments , 1998, Bioinform..

[31]  N E Morton,et al.  Parameters of the human genome. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Emmanuel Barillot,et al.  XML, bioinformatics and data integration , 2001, Bioinform..

[33]  Yong Duan,et al.  Computational protein folding: From lattice to all-atom , 2001, IBM Syst. J..

[34]  A. J. Lopez,et al.  Alternative splicing of pre-mRNA: developmental consequences and mechanisms of regulation. , 1998, Annual review of genetics.